Product Details
Alternative Name: | TNF-R 60kDa, CD120a, p55, TNFRSF 1A |
|
Clone: | H398 |
|
Host: | Mouse |
|
Isotype: | IgG2a |
|
Immunogen: | Human TNF-R1. |
|
UniProt ID: | P19438 |
|
Species reactivity: | Human
|
|
Specificity: | Recognizes membrane-bound and soluble TNF-R1. |
|
Crossreactivity: | Does not cross-react with mouse TNF-R1. |
|
Applications: | Flow Cytometry, IHC (FS), FUNC
|
|
Recommended Dilutions/Conditions: | Immunohistochemistry (frozen sections; stains acetone-fixed cryostat sections or cell smears. Recommended for H398 is the alkaline phosphatase-anti-alkaline-phosphatase (APAAP) or peroxidase anti-peroxidase (PAP) procedures or the three stage immunoperoxidase technique on acetone-fixed cryostat sections. H398 may be used at a concentration of 1-0.5mg/ml for cryostat sections) Suggested dilutions/conditions may not be available for all applications. Optimal conditions must be determined individually for each application. |
|
Application Notes: | Not recommended for IHC (PS). Functional Application: blocks TNF-R signalling. 10µg/ml H398 neutralizes TNF induced cytotoxicity on U937 (100%). Furthermore, 10µg/ml H398 neutralizes TNF induced MHC expression on K562, Colo 205 and IL2R on YT cells (always 100%). TNF induced cytotoxicity can be inhibited/neutralized by H398 on MCF-7, HeLa and L929. A working concentration could not be determined, since ascites antibody preparations have been used which exhibit an unspecific cytotoxic effect on the cells. Functional activity via the TNF-R1 is completely inhibited by H398 although on some cells the ligand still binds. Thus, the antibody H398 inhibits signalling via the receptor but not always the binding of TNF. |
|
Purity Detail: | Protein G affinity purified. |
|
Formulation: | Liquid. In PBS. |
|
Handling: | Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C. |
|
Shipping: | Blue Ice |
|
Long Term Storage: | +4°C |
|
Regulatory Status: | RUO - Research Use Only |
|
Product Literature References
Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy: C. Gajate & F. Mollinedo; J. Biol. Chem.
280, 11641 (2005),
Abstract;
Full Text
Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand: G. Lu, et al.; J. Immunol.
168, 1831 (2002),
Abstract;
Cycloheximide-induced T-cell death is mediated by a Fas-associated death domain-dependent mechanism: D. Tang, et al.; J. Biol. Chem.
274, 7245 (1999),
Abstract;
Full Text
Interferon-gamma rescues TNF-alpha-induced apoptosis mediated by up-regulation of TNFR2 on EoL-1 cells: T. Horie, et al.; Exp. Hematol.
27, 512 (1999),
Abstract;
Lipopolysaccharide mediates endothelial apoptosis by a FADD-dependent pathway: K.B. Choi, et al.; J. Biol. Chem.
273, 20185 (1998),
Abstract;
Full Text
1alpha,25-dihydroxyvitamin D3 induces sphingomyelin hydrolysis in HaCaT cells via tumor necrosis factor alpha: C.C. Geilen, et al.; J. Biol. Chem.
272, 8997 (1997),
Abstract;
Full Text
Gastrin secretion from primary cultures of rabbit antral G cells: stimulation by inflammatory cytokines: N. Weigert, et al.; Gastroenterology
110, 147 (1996),
Abstract;
TNF-induced superoxide anion production in adherent human neutrophils involves both the p55 and p75 TNF receptor: J. Richter, et al.; J. Immunol.
154, 4142 (1995),
Abstract;
Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines: D.L. Gibbons, et al.; Eur. J. Immunol.
24, 1879 (1994),
Abstract;
Cytostatic and cytotoxic effects of tumor necrosis factor alpha on MCF-7 human breast tumor cells are differently inhibited by glucocorticoid hormones: M.C. Pagliacci, et al.; Lymphokine Cytokine Res.
12, 439 (1993),
Abstract;
TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis: M. Grell, et al.; Lymphokine Cytokine Res.
12, 143 (1993),
Abstract;
Inhibition of tumor necrosis factor (TNF)-mediated NF-kappa B activation by selective blockade of the human 55-kDa TNF receptor: G. Kruppa, et al.; J. Immunol.
148, 3152 (1992),
Abstract;
Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity: G.R. Adolf & B. Fruhbeis; Cytokine
4, 180 (1992),
Abstract;
Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses: B. Thoma, et al.; J. Exp. Med.
172, 1019 (1990),
Abstract;